All 1 tracked stories fall under one category: funding. Curis is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 4 original sources each against 2.9 for the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Caleres
All 1 tracked stories fall under one category: funding. Curis is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. They are better corroborated than the beat average, carrying 4 original sources each against 2.9 for the same window. At 5, the average consequence score sits below the same-window beat average of 6.3. We currently track 1 Healthcare story that mention Caleres, all published on March 20, 2026.
Stories tracked
1
Sources per story
4
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Caleres. Shared-story counts are live from our verified record — not editorial picks.
Curis (CRIS) has successfully pivoted to a clinical-stage oncology focus, securing a cash runway into 2027 through a strategic asset sale and PIPE financing. Meanwhile, broader retail earnings from Torrid and Caleres reveal significant margin pressures from tariffs, signaling a complex macro environment for healthcare supply chains.